Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.

ESMO Open · 2023 · PMC10265606 · PMID 37285717

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significanceP > 0.05actually significant

NIVOTHYM showed that nivolumab could be a potential option more than routine standard of care in refractory type B3 thymoma or thymic carcinoma, although our results did not reach statistical significance ( P > 0.05).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.